Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study,Amyloid

当前位置： X-MOL 学术 › Amyloid › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study
Amyloid ( IF 5.5 ) Pub Date : 2023-09-05 , DOI: 10.1080/13506129.2023.2254451
Alberto Aimo _{1,

2} , Lucio Teresi _{1,

3} , Vincenzo Castiglione _{1,

2} , Anna Lisa Picerni ₂ , Martina Niccolai ₂ , Silvia Severino ₂ , Assunta Agazio ₂ , Anna Carnevale Baraglia ₄ , Laura Obici ₄ , Giovanni Palladini ₄ , Lucia Ponti _{5,

6} , Alessia Argirò _{5,

6} , Francesco Cappelli _{5,

6} , Federico Perfetto _{5,

6} , Matteo Serenelli ₇ , Giancarlo Trimarchi ₃ , Roberto Licordari ₃ , Gianluca Di Bella ₃ , Olena Chubuchna ₁ , Filippo Quattrone ₁ , Sabina Nuti ₈ , Sabina De Rosis ₈ , Claudio Passino _{1,

2} , Claudio Rapezzi _{7,

9} , Giampaolo Merlini ₄ , Michele Emdin _{1,

2} , Giuseppe Vergaro _{1,

2}

Affiliation

Transthyretin cardiac amyloidosis (ATTR-CA) has a deep impact on the quality of life (QoL), yet no specific patient-reported outcome measures (PROMs) for ATTR-CA exist.The ITALY study involved 5 It...

中文翻译：